The aim: To investigate the prognostic potential of lymphocyte-to-monocyte ratio and caspase-8 levels in prognosis of COPD development in healthy individuals.
Materials and methods: 77 individuals were involved into the study: 47 with COPD and 30 healthy volunteers. Patients underwent examination according to GOLD 2022 Guidelines. Caspase-8 serum levels were measured by ELISA. Lymphocyte-to-monocyte ratio was calculated.
Results: In crude and adjusted models lymphocyte-to-monocyte ratio and caspase-8 were associated with COPD development (respectively OR = 0.371 [95.0 % CI 0.217–0.634], p<0.006 and OR = 12.823 [95.0 % CI 2.104–78.134], p = 0.006). Additionally, systolic blood pressure had direct association with COPD (OR = 1.196 [95.0 % CI 1.028–1.391], p = 0.021). Noteworthy, diastolic blood pressure showed significant reverse association in univariate but not in multivariate analysis: OR = 0.850 [95.0 % CI 0.743–0.974] (p = 0.019) and OR = 0.820 [95.0 % CI 0.665–1.012] (p =0.064).
Conclusions: Decreased lymphocyte-to-monocyte ratio and increased caspase-8 levels are important predictors of COPD development and can serve as an additional tool for early diagnosis of COPD in healthy individuals.
The aim: To investigate the association between hypertension and serum Caspase-8 levels in COPD patients.
Materials and methods: 95 COPD patients (GOLD 2nd grade, group B) were included in the study: 47 non-hypertensive COPD patients formed the main group, and 48 patients with concomitant COPD and hypertension formed the comparison group. Patients underwent examination according to GOLD 2022 Guidelines. Caspase-8 serum levels were measured by ELISA.
Results: Performed analysis showed that an increase in Caspase-8 serum levels was significantly associated with the presence of concomitant hypertension in both univariate and multivariate analyses. A significant association was also found regarding FEV1 levels but not FVC.
Conclusions: Both presence of concomitant hypertension and spirometry parameters, which indicate the severity of COPD, can be considered strong predictors of the intensification of apoptosis in COPD patients.
grouped according to 24-hours urinary microalbumin and divided into normal 24-hours urinary microalbumin group and elevated 24-hours urinary microalbumin group to compare the clinical data of the two groups and analyze the risk factors of elevated urinary microalbumin.
Results:The 24-hours urinary microalbumin was positively associated with lipid accumulation product and visceral adiposity index in patients with essential hypertension(all P < 0.01). The risk of elevated 24-hours urinary microalbumin may increase with increasing lipid accumulation product,visceral adiposity index. After adjusting for age,sex,admission systolic blood pressure,admission diastolic blood pressure,body mass index,triglycerides,high density lipoprotein cholesterol,serum creatinine,the OR (95%CI) of lipid accumulation product in the fourth quantile group was 4.770 (1.680~13.545) compared with the first quantile of lipid accumulation product. The OR (95%CI) values of visceral adiposity index in the second,third and fourth quartile groups were 3.364 (1.330~8.512),3.440 (1.249~9.472),and 5.213 (1.556~17.461),compared with the first quartile group of visceral adiposity index. Analysis of the receiver operating characteristic curve suggested that the risk of elevated urinary microalbumin increases when the lipid accumulation product is greater than 32.236 and the visceral adiposity index is greater than 2.031.
Conclusion:When the lipid accumulation product and visceral adiposity index increase in patients with essential hypertension, they may lead to an increased risk of increased urinary microalbumin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.